BMY
Bristol-Myers Squibb Company
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
-1/100
Last price
59.59
▲ 0.78 (1.33%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
58.80
Prev close
58.81
Day high
59.60
Day low
58.65
Volume
9.89M
Market cap
$121.73B
P/E (TTM)
12.95
52W range
42.52 – 68.64
Day trading desk
Gap from prior close
-0.02%
Prior close 58.81
VWAP
59.39
+0.33% from price
Relative volume
1.87×
Unusually busy
Session range
1.68%
58.61 – 59.60
Position in range
100%
Near session high
ATR (14D)
1.45
2.43% of price
Prior day high
60.15
PDH
Prior day low
58.33
PDL
Bid / ask spread
—
Quote not published
Session volume
20.86M
Avg 11.17M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.20%
-7.2%
1M
-10.82%
-12.0%
3M
+3.56%
-1.0%
6M
+3.33%
-14.9%
YTD
+10.47%
-3.8%
1Y
+31.11%
+14.7%
3Y
+2.67%
-79.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on BMY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+76.59K
Net buying
Buy transactions
6
83.34K shares
Sell transactions
2
6.75K shares
Net transactions
+8
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
1.98M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 9, 26 | MASSACESI CRISTIAN Officer |
SELL | 6.25K | $403.50K | Direct |
| Sep 1, 26 | SHORT BARTIE WENDY Officer |
CONVERSION | 1.24K | $82.71K | Direct |
| Aug 25, 26 | HOLZER PHIL M Officer |
SELL | 500 | $33.75K | Direct |
| Jul 31, 26 | GALLMAN CARI General Counsel |
— | 1.06K | — | Direct |
| Jul 31, 26 | MASSACESI CRISTIAN Officer |
— | 51.17K | — | Direct |
| Jun 15, 26 | HALLER JULIA A Director |
CONVERSION | 20.46K | $1.10M | Direct |
| Jun 3, 26 | SHORT BARTIE WENDY Officer |
— | 8.04K | — | Direct |
| May 1, 26 | LENKOWSKY ADAM Officer |
— | 1.37K | — | Direct |
| Apr 1, 26 | ELKINS DAVID VINCENT Chief Financial Officer |
SELL | 30.00K | $1.85M | Direct |
| Apr 1, 26 | SHANAHAN KARIN Officer |
— | 3.31K | — | Direct |
| Mar 10, 26 | GALLMAN CARI General Counsel |
— | 6.98K | — | Direct |
| Mar 10, 26 | HOCH LYNELLE BAUMGARDNER Officer |
— | 8.19K | — | Direct |
| Mar 10, 26 | POOLE AHN AMANDA Officer |
— | 6.44K | — | Direct |
| Mar 10, 26 | HOLZER PHIL M Officer |
— | 6.19K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOERNER CHRISTOPHER S |
Chief Executive Officer | 146.89K | Conversion of Exercise of derivative security |
ELKINS DAVID VINCENT |
Chief Financial Officer | 159.54K | Sale |
HALLER JULIA A |
Director | 34.08K | Conversion of Exercise of derivative security |
HIRAWAT SAMIT |
Officer | 83.51K | Purchase |
LENKOWSKY ADAM |
Officer | 28.68K | Conversion of Exercise of derivative security |
LEUNG SANDRA |
General Counsel | 465.37K | Conversion of Exercise of derivative security |
MASSACESI CRISTIAN |
Officer | 25.00K | Conversion of Exercise of derivative security |
MEYERS GREGORY SCOTT |
Chief Technology Officer | 30.36K | Conversion of Exercise of derivative security |
PLENGE ROBERT M |
Officer | 24.75K | Conversion of Exercise of derivative security |
SHANAHAN KARIN |
Officer | 27.34K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$121.73B
Enterprise value$155.71B
Revenue (TTM)$49.19B
Gross profit$35.25B
EBITDA$18.93B
Net income$9.28B
EPS (TTM)$4.60
Free cash flow$8.11B
Total cash$11.07B
Total debt$45.05B
Book value / share$10.93
Shares outstanding2.04B
Float2.04B
Short % of float2.06%
Dividend yield4.29%
Beta (5Y)0.18
Valuation & profitability ratios
Trailing P/E12.95
Forward P/E9.08
PEG ratio16.37
Price / sales—
Price / book5.45
EV / revenue3.17
EV / EBITDA8.23
Gross margin71.66%
Operating margin34.42%
Profit margin18.87%
Return on equity46.60%
Return on assets10.72%
Debt / equity201.86
Current ratio1.53
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $48.20B | $48.30B | $45.01B | $46.16B | -0.2% |
| Operating revenue | $47.20B | $47.26B | $44.39B | $45.41B | -0.1% |
| Cost of revenue | $13.94B | $13.97B | $10.69B | $10.14B | -0.2% |
| Gross profit | $34.26B | $34.33B | $34.31B | $36.02B | -0.2% |
| Research & development | $9.95B | $11.16B | $9.30B | $9.51B | -10.8% |
| Selling, general & admin | $7.27B | $8.41B | $7.77B | $7.81B | -13.6% |
| Total operating expense | $20.54B | $28.45B | $26.12B | $26.92B | -27.8% |
| Operating income | $13.72B | $5.89B | $8.20B | $9.10B | +133.1% |
| Net interest income | -$1.89B | -$1.95B | -$1.17B | -$1.23B | +2.9% |
| Pre-tax income | $9.33B | -$8.38B | $8.44B | $7.71B | +211.3% |
| Tax provision | $2.27B | $554.00M | $400.00M | $1.37B | +310.1% |
| Net income | $7.05B | -$8.95B | $8.03B | $6.33B | +178.8% |
| Net income to common | $7.05B | -$8.95B | $8.03B | $6.33B | +178.8% |
| Basic EPS | 3.47 | -4.41 | 3.88 | 2.97 | +178.7% |
| Diluted EPS | 3.46 | -4.41 | 3.86 | 2.95 | +178.5% |
| EBIT | $11.22B | -$6.43B | $9.61B | $8.95B | +274.4% |
| EBITDA | $15.23B | $3.17B | $19.37B | $19.22B | +380.7% |
| Basic shares | 2.03B | 2.03B | 2.07B | 2.13B | +0.3% |
| Diluted shares | 2.04B | 2.03B | 2.08B | 2.15B | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $10.21B | $10.35B | $11.46B | $9.12B | -1.3% |
| Cash & short-term investments | $10.67B | $10.86B | $12.28B | $9.25B | -1.7% |
| Accounts receivable | $9.59B | $9.01B | $8.88B | $8.15B | +6.4% |
| Inventory | $2.69B | $2.56B | $2.66B | $2.34B | +5.2% |
| Total current assets | $29.39B | $29.78B | $31.77B | $27.27B | -1.3% |
| Property, plant & equipment | $9.13B | $8.36B | $8.04B | $7.47B | +9.2% |
| Goodwill & intangibles | $41.11B | $45.36B | $48.65B | $57.50B | -9.4% |
| Total assets | $90.04B | $92.60B | $95.16B | $96.82B | -2.8% |
| Total current liabilities | $23.42B | $23.77B | $22.26B | $21.89B | -1.5% |
| Current debt | $2.26B | $2.05B | $3.12B | $4.26B | +10.5% |
| Long-term debt | $42.85B | $47.60B | $36.65B | $35.06B | -10.0% |
| Total debt | $47.14B | $51.20B | $41.46B | $40.72B | -7.9% |
| Total liabilities | $71.53B | $76.22B | $65.67B | $65.70B | -6.1% |
| Retained earnings | $16.90B | $14.91B | $28.77B | $25.50B | +13.3% |
| Shareholder equity | $18.47B | $16.34B | $29.43B | $31.06B | +13.1% |
| Working capital | $5.97B | $6.01B | $9.51B | $5.38B | -0.5% |
| Net tangible assets | -$22.63B | -$29.03B | -$19.22B | -$26.44B | +22.0% |
| Shares issued | 2.92B | 2.92B | 2.92B | 2.90B | -0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $7.05B | -$8.93B | $8.04B | $6.34B | +179.0% |
| Depreciation & amortisation | $4.01B | $9.60B | $9.76B | $10.28B | -58.2% |
| Stock-based compensation | $553.00M | $507.00M | $518.00M | $457.00M | +9.1% |
| Change in working capital | -$455.00M | $810.00M | -$1.91B | -$2.23B | -156.2% |
| Operating cash flow | $14.16B | $15.19B | $13.86B | $13.07B | -6.8% |
| Capital expenditure | -$1.31B | -$1.25B | -$1.21B | -$1.12B | -5.0% |
| Investing cash flow | -$4.13B | -$21.35B | -$2.29B | -$1.06B | +80.6% |
| Share buybacks | $0 | $0 | -$5.16B | -$8.00B | — |
| Dividends paid | -$5.04B | -$4.86B | -$4.74B | -$4.63B | -3.7% |
| Financing cash flow | -$10.35B | $5.13B | -$9.42B | -$16.96B | -301.8% |
| Free cash flow | $12.85B | $13.94B | $12.65B | $11.95B | -7.9% |
| End cash position | $10.22B | $10.35B | $11.52B | $9.32B | -1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | +12.9% |
| Operating revenue | $12.69B | $11.26B | $12.23B | $11.97B | $12.03B | +12.7% |
| Cost of revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | +8.9% |
| Gross profit | $9.25B | $8.07B | $8.41B | $8.79B | $8.90B | +14.6% |
| Research & development | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | +11.7% |
| Selling, general & admin | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | +12.9% |
| Total operating expense | $5.22B | $4.70B | $5.59B | $5.15B | $5.12B | +11.0% |
| Operating income | $4.03B | $3.37B | $2.81B | $3.64B | $3.77B | +19.6% |
| Net interest income | -$407.00M | -$411.00M | -$432.00M | -$480.00M | -$485.00M | +1.0% |
| Pre-tax income | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | +26.1% |
| Tax provision | $770.00M | $561.00M | $384.00M | $919.00M | $460.00M | +37.3% |
| Net income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | +23.9% |
| Net income to common | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | +23.9% |
| Basic EPS | 1.62 | 1.31 | 0.53 | 1.08 | 0.64 | +23.7% |
| Diluted EPS | 1.62 | 1.31 | 0.53 | 1.08 | 0.64 | +23.7% |
| EBIT | $4.49B | $3.65B | $1.90B | $3.59B | $2.26B | +23.1% |
| EBITDA | $5.09B | $4.25B | $2.88B | $4.61B | $3.27B | +19.8% |
| Basic shares | 2.04B | 2.04B | 2.04B | 2.04B | 2.04B | +0.2% |
| Diluted shares | 2.05B | 2.05B | 2.04B | 2.04B | 2.04B | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.72B | $9.57B | $10.21B | $15.73B | $12.60B | -8.9% |
| Cash & short-term investments | $11.07B | $10.49B | $10.67B | $16.50B | $13.60B | +5.5% |
| Accounts receivable | $9.08B | $7.95B | $9.59B | $9.62B | $9.71B | +14.2% |
| Inventory | $2.74B | $2.76B | $2.69B | $2.76B | $2.74B | -0.7% |
| Total current assets | $28.58B | $27.21B | $29.39B | $35.63B | $33.22B | +5.0% |
| Property, plant & equipment | $9.28B | $9.19B | $9.13B | $8.95B | $8.65B | +1.0% |
| Goodwill & intangibles | $39.37B | $40.23B | $41.11B | $42.47B | $43.44B | -2.2% |
| Total assets | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | +1.3% |
| Total current liabilities | $18.66B | $19.16B | $23.42B | $28.14B | $27.53B | -2.6% |
| Current debt | $1.03B | $2.31B | $2.26B | $4.51B | $4.71B | -55.5% |
| Long-term debt | $42.09B | $42.15B | $42.85B | $44.47B | $44.47B | -0.1% |
| Total debt | $45.05B | $46.43B | $47.14B | $51.04B | $50.93B | -3.0% |
| Total liabilities | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B | -1.6% |
| Retained earnings | $20.32B | $18.29B | $16.90B | $17.09B | $16.15B | +11.1% |
| Shareholder equity | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B | +11.2% |
| Working capital | $9.92B | $8.05B | $5.97B | $7.49B | $5.69B | +23.2% |
| Net tangible assets | -$17.05B | -$20.16B | -$22.63B | -$23.92B | -$26.00B | +15.5% |
| Shares issued | 2.04B | 2.92B | 2.92B | 2.92B | 2.92B | -30.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $3.32B | $2.68B | $1.08B | $2.19B | $1.31B | +23.8% |
| Depreciation & amortisation | $594.00M | $594.00M | $977.00M | $1.01B | $1.01B | 0.0% |
| Stock-based compensation | $135.00M | $146.00M | $133.00M | $139.00M | $137.00M | -7.5% |
| Change in working capital | -$624.00M | -$2.83B | -$1.65B | $3.06B | $15.00M | +78.0% |
| Operating cash flow | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B | +207.3% |
| Capital expenditure | -$305.00M | -$347.00M | -$370.00M | -$320.00M | -$361.00M | +12.1% |
| Investing cash flow | -$1.61B | -$131.00M | -$1.46B | -$1.70B | -$473.00M | -1,132.1% |
| Dividends paid | -$1.29B | -$1.28B | -$1.26B | -$1.26B | -$1.26B | -0.3% |
| Financing cash flow | -$2.63B | -$1.56B | -$6.03B | -$1.49B | -$1.84B | -68.6% |
| Free cash flow | $3.09B | $757.00M | $1.60B | $5.99B | $3.56B | +307.9% |
| End cash position | $8.72B | $9.58B | $10.22B | $15.73B | $12.61B | -9.0% |
Options analytics
Put / call volume
1.85
Put-heavy session
Put / call open interest
0.32
Positioning, not flow
Max pain
61.00
+2.4% from spot
ATM implied vol
36.4%
Nearest strike to spot
Skew (10% OTM)
+20.3%
Puts bid over calls
Call volume
827
Contracts, this expiry
Put volume
1.53K
Contracts, this expiry
Heaviest call OI
65.00
5.45K contracts
Heaviest put OI
59.00
1.40K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.60 | 2.04 | +27.7% |
| Mar 2026 | 1.42 | 1.58 | +11.2% |
| Dec 2025 | 1.20 | 1.26 | +4.6% |
| Sep 2025 | 1.52 | 1.63 | +7.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.73 | 22 | $12.66B | +3.6% |
| Next quarter | 1.60 | 22 | $12.70B | +1.6% |
| Current year | 6.95 | 28 | $49.85B | +3.4% |
| Next year | 6.59 | 28 | $48.31B | -3.1% |
Analyst targets & ownership
Mean target$66.13
High target$82.00
Low target$40.00
Implied upside10.96%
Analyst count24
ConsensusHOLD
Strong buy / Buy3 / 6
Hold18
Sell / Strong sell1 / 0
Held by insiders0.10%
Held by institutions84.88%
Institutions holding3.26K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
61.57
-3.21% from price
SMA 20
62.48
-4.63% from price
SMA 50
64.38
-7.44% from price
SMA 100
60.98
-2.27% from price
SMA 200
59.45
+0.24% from price
EMA 12
61.59
-3.24% from price
EMA 26
62.73
-5.00% from price
EMA 50
62.87
-5.21% from price
RSI (14)
34.9
Neutral
MACD (12,26,9)
-1.14
Hist -0.36
ATR (14)
1.45
2.43% of price
Realised vol 30D
20.8%
Annualised
Bollinger upper
65.39
20, 2σ
Bollinger lower
59.58
20, 2σ
50 / 200 cross
Golden
64.38 vs 59.45
Trend bias
Above 200
+0.24%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.23
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
20.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-13.6%
Peak to trough
Max drawdown 5Y
-51.1%
Peak to trough
ATR 14
1.45
2.43% of price
Beta (reported)
0.18
5Y monthly, from filing
Short interest
Shares short
41.97M
Prior 45.85M
Change vs prior
-8.5%
Shorts covering
% of float
2.06%
Normal
% of shares out
2.05%
Against total outstanding
Days to cover
5.4
Crowded exit
Float
2.04B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Sep 16, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Sep 10, 26 | HSBC | MAINTAINED | Hold | Hold |
| Aug 5, 26 | Argus Research | UPGRADE | Hold | Buy |
| Aug 3, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Jul 31, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Jul 31, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 31, 26 | Cantor Fitzgerald | MAINTAINED | Neutral | Neutral |
| Jul 31, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Jul 31, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 31, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 10, 26 | B of A Securities | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate$2.52 / yr
Forward yield4.29%
5-year avg yield3.84%
Payout ratio55.29%
Ex-dividend dateOct 2, 2026
Next pay dateNov 2, 2026
Last split1000000:951777
Split dateAug 7, 2001
SEC filings
Periodic Financial Reports
10-Q · 2026-07-30
Annual report of employee stock purchase
11-K · 2026-06-05
Corporate Changes & Voting Matters
8-K · 2026-05-08
Corporate Changes & Voting Matters
8-K · 2026-04-30
Proxy Statements
DEFA14A · 2026-04-17
Notice of termination of registration of a class of securities under Section 12(g)
15-12G · 2026-03-27
Proxy Statements
DEF 14A · 2026-03-25
Periodic Financial Reports
10-K · 2026-02-11
Headlines
Sotyktu Gains Ground in Psoriatic Arthritis, but Rheumatologists Remain Selective as Its Role in the Treatment Algorithm Takes Shape, According to Spherix Global Insights
GlobeNewswire · 7h ago
Lila Bio Expands Leadership Team with Kimberly Ma, M.S., as Chief Development Officer
Business Wire · 14h ago
Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA
Zacks · 21h ago
Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here’s Why it Matters
Insider Monkey · 1d ago
Bristol-Myers Squibb Shares Fall After Leerink Partners Downgrade
MT Newswires · 1d ago
CN Bio Announces Expert Speaker Line-Up and Scientific Program for Inaugural Organ-on-a-Chip e-Symposium
Business Wire · 1d ago
BMY or ARGX: Which Is the Better Value Stock Right Now?
Zacks · 1d ago
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt
Investing.com · 2d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.